financetom
Business
financetom
/
Business
/
TransUnion Raises Outlook As CEO Highlights Strongest Growth Since 2021
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TransUnion Raises Outlook As CEO Highlights Strongest Growth Since 2021
Oct 23, 2025 6:35 AM

TransUnion ( TRU ) reported its third-quarter results on Thursday before market open, beating Wall Street estimates on both earnings and revenue.

The company reported adjusted earnings of $1.10 per share, exceeding the consensus estimate of $1.04 and marking a 5.8% increase from $1.04 per share in the same period last year.

Revenue for the quarter totaled $1.17 billion, beating analysts’ expectations of $1.13 billion and representing a 7.8% year-over-year increase from $1.08 billion in the prior-year quarter.

Also Read: TransUnion Hack Exposes Data Of 4.4 Million Consumers As UnitedHealth, Microsoft Breaches Highlight Escalating Crisis

TransUnion’s quarterly adjusted EBITDA margin stood at 36.3%, unchanged from 36.3% in the third quarter of 2024.

The company had cash and cash equivalents of $750 million as of September 30.

The company has repurchased $200 million in shares year-to-date and raised its share repurchase authorization up to $1 billion.

Segment Performance

In the third quarter of 2025, total revenue for U.S. Markets rose 8% year-over-year to $913 million, reflecting solid performance in Financial Services and Emerging Verticals, partially offset by a decline in Consumer Interactive.

Financial Services revenue increased 19% to $438 million, and Emerging Verticals grew 7% to $330 million, while Consumer Interactive fell 17% on a reported basis and 18% organically to $145 million.

U.S. Markets adjusted EBITDA grew 10% to $351 million, supported by strong gains in core segments.

International revenue also advanced 8% to $260 million, or 6% on an organic constant-currency basis. The United Kingdom led growth with a 24% reported gain to $71 million (11% organic), followed by Africa up 14% to $19 million and Canada up 11% in constant currency to $43 million.

India delivered modest 5% organic growth with flat reported revenue of $69 million, while Latin America remained steady and Asia Pacific declined 8%. International adjusted EBITDA increased 2% to $112 million, reflecting modest organic growth of 3%.

Outlook

TransUnion ( TRU ) expects fourth-quarter adjusted EPS of $0.97 to $1.02, aligning with the analyst consensus of $0.99. The company anticipates sales of $1.12 billion to $1.14 billion, exceeding the $1.11 billion estimate.

For full-year 2025, TransUnion ( TRU ) raised its adjusted EPS forecast to $4.19–$4.25, up from the previous range of $4.03–$4.14, and slightly above the analyst estimate of $4.18.

Revenue guidance was also lifted to $4.52 billion–$4.54 billion, compared with the prior range of $4.43 billion–$4.47 billion, surpassing the consensus estimate of $4.48 billion.

CEO Commentary

Chris Cartwright, president and CEO, stated, “In the third quarter, TransUnion ( TRU ) delivered strong results that again exceeded financial guidance. Revenue growth was 8%; excluding last year’s large breach remediation win, organic constant currency growth was 11%, our strongest underlying growth since 2021.”

“Financial Services and Emerging Verticals growth accelerated to 19% and 7.5%, respectively. International grew 6% on an organic constant currency basis, with double-digit growth in the UK, Canada and Africa,” Cartwright added.

Price Action: TRU shares were trading higher by 5.37% to $85.00 premarket at last check Thursday.

Read Next:

Nvidia’s New Partner And Rival: Intel, AMD Witness Improving Technical Indicators Amid Solid Momentum Gains

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck expects over $5 billion commercial opportunity from Cidara's flu drug
Merck expects over $5 billion commercial opportunity from Cidara's flu drug
Nov 17, 2025
Nov 17 (Reuters) - Merck ( MRK ) said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' ( CDTX ) experimental flu drug. The drugmaker struck a deal worth nearly $9.2 billion last week to acquire Cidara to gain access to the long-acting antiviral drug, CD388, currently in late-stage trial. ...
BRIEF-Itron Signs Definitive Agreement To Acquire Locusview, Ltd.
BRIEF-Itron Signs Definitive Agreement To Acquire Locusview, Ltd.
Nov 17, 2025
Itron Inc ( ITRI ): * ITRON SIGNS DEFINITIVE AGREEMENT TO ACQUIRE LOCUSVIEW, LTD. * ITRON INC ( ITRI ): PURCHASE PRICE FOR ACQUISITION IS $525 MILLION AND WILL BE FUNDED THROUGH CASH ON HAND Source text: Further company coverage: ...
BRIEF-Colony Bankcorp, Inc. And TC Bancshares, Inc. Announce Regulatory And Shareholder Approvals Received For Merger
BRIEF-Colony Bankcorp, Inc. And TC Bancshares, Inc. Announce Regulatory And Shareholder Approvals Received For Merger
Nov 17, 2025
Colony Bankcorp Inc ( CBAN ): * COLONY BANKCORP, INC. ( CBAN ) AND TC BANCSHARES, INC. ( TCBC ) ANNOUNCE REGULATORY AND SHAREHOLDER APPROVALS RECEIVED FOR MERGER Source text: Further company coverage: ...
Coppernico Metals Launches Field Exploration at Select Targets at Sombrero Project, Peru
Coppernico Metals Launches Field Exploration at Select Targets at Sombrero Project, Peru
Nov 17, 2025
08:31 AM EST, 11/17/2025 (MT Newswires) -- Coppernico Metals ( CPPMF ) said Monday that it has begun a comprehensive field exploration program at the Nioc and Antapampa targets within the Sombrero Project in Peru. The objective is to expand and better define known surface mineralization at Nioc, characterize the geochemical footprint of the larger skarn system, and identify and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved